Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
‘The Price of Business’: Alex Brill Talks Rising Inflation

‘The Price of Business’: Alex Brill Talks Rising Inflation

Apr 21, 2022 | Interviews

On April 21, Alex Brill made a special appearance on “The Price of Business” radio show to talk about the sharp rise of inflation and its effects on small businesses and individuals earning low wages.

MGA’s Alex Brill on CNBC’s Squawk Box

MGA’s Alex Brill on CNBC’s Squawk Box

Jul 9, 2019 | Interviews

Today, Brill discusses President Trump’s potential appointment options for the Federal Reserve Board of Governors.

Next Entries »
  • Analysis (54)
  • Books (3)
  • Commentary (15)
  • Events (21)
  • Interviews (60)
  • News (55)
  • Op-Eds (98)
  • Press Releases (4)
  • Testimony (21)
  • PBMs Pass Through Rebates
    MGA Brief Examines State and Federal PBM MandatesDecember 1, 2025
  • FDA Moves to Facilitate Biosimilar Development
    FDA Moves to Facilitate Biosimilar DevelopmentOctober 30, 2025
  • How Pharmaceutical Tariffs Will Affect US Health Care Costs
    How Pharmaceutical Tariffs Will Affect US Health Care CostsSeptember 26, 2025
  • Quantifying the economic impact of healthcare distributors
    MGA Releases New Report Quantifying the Economic Impact of Healthcare DistributorsSeptember 17, 2025
  • Unsung Hero of the OBBBA
    The Unsung Hero of the OBBBA: Permanent ExpensingAugust 20, 2025
  • Alex Brill Interviewed by Biosimilars Review & Report
    Alex Brill Interviewed by Biosimilars Review & ReportAugust 6, 2025
  • Medicare Price Negotiations and Drug Competition
    MGA Releases New White Paper on Medicare Price Negotiations and Drug CompetitionJuly 14, 2025
  • effects of 304B
    The 340B Program’s Negative Impact on Pharmaceutical InnovationJune 5, 2025
  • a conversation on tax reform
    A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax ReformMarch 5, 2025
  • US Biosimilars Market
    New MGA Paper Identifies Barriers to US Biosimilar Success in the Second DecadeMarch 5, 2025
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact